Case Studies
AHA Again Urges HHS to Protect 340B Program From Drug Companies’ Actions
September 8, 2020
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members. While we understand that the Health Resources and Services Administration (HRSA) is further investigating these actions, we urge swift and decisive action to halt these pernicious tactics so as to prevent other manufacturers from following suit.
Key Resources
Related Resources
Letter/Comment
Letter/Comment
Case Studies